The clinical pharmacology of hexamethylmelamine: Phase I study.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000633:toxicity*; D001806:Blood Urea Nitrogen; D004285:Dogs; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D000882:Haplorhini; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D051379:Mice; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced; D051381:Rats; D014265:Triethylenemelamine / Q000009:adverse effects* / Q000633:toxicity*; D014527:Uric Acid / Q000097:blood; D014556:Urine / Q000032:analysis
D000970:Antineoplastic Agents; D014527:Uric Acid; D014265:Triethylenemelamine